
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health is a leading player in the fast-growing value-based care market, and its unique risk appetite in the underpenetrated specialty care market makes it well-positioned for growth. The company has strong barriers to entry due to its proprietary technology and partnerships with large health plans. With a diverse range of solutions and the ability to cross-sell and upsell to its large customers, as well as add new contracts, Evolent has an attractive growth proposition. Early indications show strong top-line growth expectations for 2026, leading to a potential normalized margin of 7-10% in 2027 and beyond, presenting significant upside for investors. Additionally, the company has a solid balance sheet and potential cash generation to help manage any potential leverage challenges. Despite a more conservative posture towards reserves, the company is set up for outsized growth in the coming years, which suggests a positive outlook for investors.
Bears say
Evolent Health is facing challenges with their specialty care management services, leading to a decline in revenue and a 5% underperformance in their 2026 results. The company's recent shift to a more conservative posture under their new CFO may provide more consistency in earnings, but their current financial outlook justifies a negative market outlook. With a decline in revenue and adjusted EBITDA estimates and a 10x EV/EBITDA multiple for their 2027 EBITDA estimate, our updated price target for Evolent Health is $6 per share.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares